A cascade of new findings is reshaping the global cancer conversation, shifting attention from treatment alone to a broader armoury that includes prevention, drug repurposing and long-term vigilance. Viewed from Milan, where delegates gathered for a Novartis-sponsored talk during the city’s Health Week, the immediate message was one of progress: Italy’s five-year breast cancer survival rate has reached 86%, among the highest in Europe. Yet specialists underscored a sobering caveat — roughly one in five women still faces a recurrence within a decade of diagnosis, making sustained, active management essential.

The prevention front, however, gained its most emphatic voice from Argentina. In an interview with Radio Mitre, the 97-year-old Italian oncologist Silvio Garattini, founder of the Mario Negri Institute, declared that “forty per cent of cancers are due to our current lifestyle.” He pointed to tobacco, alcohol, obesity, sedentarism and poor diet as clear triggers, along with certain infections, lamenting that society knows what to do but fails to act, partly because of market-driven confusion around health information. His insistence on quotidian change as a central weapon against tumours resonated well beyond Latin America, reinforcing a message that public-health officials in London and Washington have been amplifying: prevention is not a supplementary gesture but a core clinical strategy.

From Russia came a startling illustration of how old drugs can learn new tricks. Researchers, publishing in the British Journal of Clinical Pharmacology, analysed 22 studies and found that mebendazole, a widely used anti-parasitic, slowed the growth of brain tumours in laboratory mice and doubled their survival. The compound proved effective against glioblastoma, medulloblastoma, meningioma and diffuse midline glioma, in some experiments eliminating tumours entirely for prolonged periods when combined with radiotherapy. The drug appears to destabilise cellular scaffolding, block blood-vessel formation and disrupt other pathways essential to tumour survival. Scientists in Moscow view such repurposing as a low-cost, high-return avenue that could bypass the decade-long timelines of novel drug development.

A parallel story of pharmacological cross-purposing emerged from studies unveiled at the world’s largest cancer conference and reported by Iranian media. Three new investigations indicated that GLP-1 receptor agonists — the class of weight-loss drugs already transforming obesity care — may cut breast cancer risk by up to 30 per cent. One study found that patients using these injections were significantly less likely to develop the disease, which remains the most common cancer globally. A second trial suggested that adding the drugs to existing oncological regimens could improve outcomes, while a third pointed to a broader reduction in cancer-related mortality. Health analysts in the Gulf note that these results, if confirmed in larger trials, could redefine the interface between metabolic and oncological medicine.

Taken together, the disparate advances converge on a unifying insight: the battle against cancer is becoming more systemic, linking everyday habits, existing drug libraries and long-term monitoring. The Italian data on recurrence remind practitioners that survival does not equate to a cure; the Argentine oncologist’s plea for prevention underscores what patients can do today; and the repurposed drugs from Russian and international research offer hope for the hardest-to-treat tumours. For a globally literate readership, the picture is neither a miracle nor a dead end, but a pragmatic enlargement of the arsenal — one where a deworming pill and a diabetes injection sit alongside lifestyle coaching and next-generation immunotherapy.